Law Firm Investigates GeneDx for Securities Violations After 49% Stock Plunge
WGS sits 50% above its 52-week low of $32.21.
Summary
Shareholder rights law firm Hagens Berman has launched an investigation into GeneDx Holdings for potential federal securities law violations. This follows a 49% stock price decline on May 5th, triggered by the company's Q1 2026 earnings miss, a tenfold increase in net loss, and a significant cut to full-year guidance. The firm is probing whether management misled investors regarding key changes in product mix and growth expectations. This investigation introduces new legal and reputational risks for GeneDx, adding to the uncertainty following its recent financial disappointments.
At the time of this announcement, WGS was trading at $48.18 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.4B. The 52-week trading range was $32.21 to $170.87. This news item was assessed with negative market sentiment and an importance score of 8 out of 10. Source: PR Newswire.